<![CDATA[EYLEA 8mg in RVO: QUASAR clinical perspectives video]]>
Prof Gale: So, the 64-week data that maybe the headline of it is the improvement in visual acuity. Could you explain to us how you feel that the improvement of visual acuity stacks up for our patients and against other clinical trials? Prof Chaudhary: …